{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T09:21:42Z","timestamp":1781169702901,"version":"3.54.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["T-B-040"],"award-info":[{"award-number":["T-B-040"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.cca.2025.120435","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T15:35:00Z","timestamp":1750260900000},"page":"120435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Comparative study and relevant exploration on methods for establishing unfractionated heparin therapeutic range (HTR) based on APTT"],"prefix":"10.1016","volume":"577","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8632-9425","authenticated-orcid":false,"given":"Zixin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dabuxilite","family":"Bayartaikishigtai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengqiang","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaowa","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7674-9857","authenticated-orcid":false,"given":"Zhou","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.cca.2025.120435_b0005","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1055\/s-0044-1786990","article-title":"Pleiotropic Effects of Heparin and its monitoring in the clinical practice","volume":"50","author":"Arachchillage","year":"2024","journal-title":"Semin. Thromb. Hemost."},{"issue":"3","key":"10.1016\/j.cca.2025.120435_b0010","first-page":"253","article-title":"Activated Partial Thromboplastin Time monitoring of Unfractionated Heparin Therapy: issues and Recommendations","volume":"43","author":"Marlar","year":"2017","journal-title":"Semin. Thromb. Hemost."},{"issue":"8","key":"10.1016\/j.cca.2025.120435_b0015","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1080\/14656566.2024.2364057","article-title":"Clinical guidance for unfractionated heparin dosing and monitoring in critically ill patients","volume":"25","author":"Samimi","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.cca.2025.120435_b0020","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/978-1-0716-3175-1_22","article-title":"An Overview of Heparin monitoring with the Anti-Xa Assay","volume":"2663","author":"Dean","year":"2023","journal-title":"Methods Mol. Biol."},{"issue":"3","key":"10.1016\/j.cca.2025.120435_b0025","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood.V96.3.846","article-title":"Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range","volume":"96","author":"Greinacher","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cca.2025.120435_b0030","first-page":"547","article-title":"Monitoring unfractionated heparin with the aPTT: time for a fresh look","volume":"96","author":"Eikelboom","year":"2006","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.cca.2025.120435_b0035","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/1076029616679508","article-title":"Protocolled Redefinition of the Therapeutic Range for Unfractionated Heparin: lost in translation?","volume":"24","author":"Coene","year":"2018","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"3","key":"10.1016\/j.cca.2025.120435_b0040","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MAT.0000000000001652","article-title":"2021 ELSO Adult and Pediatric Anticoagulation guidelines","volume":"68","author":"Mcmichael","year":"2022","journal-title":"ASAIO J."},{"issue":"3","key":"10.1016\/j.cca.2025.120435_b0045","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1055\/a-2359-0987","article-title":"Management of therapeutic-intensity unfractionated heparin: a narrative review on critical points","volume":"8","author":"Gouin-Thibault","year":"2024","journal-title":"TH Open"},{"issue":"8","key":"10.1016\/j.cca.2025.120435_b0050","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1111\/jth.15264","article-title":"APTT therapeutic range for monitoring unfractionated heparin therapy. significant impact of the anti-Xa reagent used for correlation","volume":"19","author":"Toulon","year":"2021","journal-title":"J. Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.cca.2025.120435_b0055","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/1076029617741363","article-title":"Performance of anti-factor Xa versus activated partial thromboplastin time for heparin monitoring using multiple nomograms","volume":"24","author":"Whitman-Purves","year":"2018","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"6","key":"10.1016\/j.cca.2025.120435_b0060","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/j.1875-9114.2011.01049.x","article-title":"Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin","volume":"32","author":"Vandiver","year":"2012","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.cca.2025.120435_b0065","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5045\/br.2016.51.3.171","article-title":"Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy","volume":"51","author":"Byun","year":"2016","journal-title":"Blood Res"},{"issue":"5","key":"10.1016\/j.cca.2025.120435_b0070","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jtha.2025.02.012","article-title":"Results of an international survey on the management of therapeutic intensity unfractionated heparin: communication from the SSCs of the ISTH","volume":"23","author":"Gouin-Thibault","year":"2025","journal-title":"J. Thromb. Haemost."},{"issue":"3 Suppl","key":"10.1016\/j.cca.2025.120435_b0075","article-title":"Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Hirsh","year":"2004","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.cca.2025.120435_b0080","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1309\/AJCP60ZGXCJKRMJO","article-title":"Inaccuracy of a \u201cspiked curve\u201d for monitoring unfractionated heparin therapy","volume":"135","author":"Gausman","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.cca.2025.120435_b0085","series-title":"On-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) test","author":"Institute C a L S","year":"2008"},{"issue":"1","key":"10.1016\/j.cca.2025.120435_b0090","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5858\/arpa.2011-0516-OA","article-title":"The optimum number and types of plasma samples necessary for an accurate activated partial thromboplastin time-based heparin therapeutic range","volume":"137","author":"Marlar","year":"2013","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"3","key":"10.1016\/j.cca.2025.120435_b0095","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1309\/RRQKT2JEYV33D19D","article-title":"Effect on routine and special coagulation testing values of citrate anticoagulant adjustment in patients with high hematocrit values","volume":"126","author":"Marlar","year":"2006","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.cca.2025.120435_b0100","series-title":"Collection, Transport, And Pro-Cessing Of Blood Specimens For Testing Plasma-Based Coagulation Assays And Molecular Hemostasis Assays: Approved Guideline-Fifth Edition","author":"Institute C a L S","year":"2008"},{"issue":"3","key":"10.1016\/j.cca.2025.120435_b0105","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/ajcp\/84.3.351","article-title":"Heparin monitoring by activated partial thromboplastin time. Comparison of ex vivo measurement and in vitro standardization","volume":"84","author":"Scialla","year":"1985","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.cca.2025.120435_b0110","article-title":"Performance of 6 routine coagulation assays on the new Roche Cobas t711 analyzer","volume":"17","author":"Oostendorp","year":"2019","journal-title":"Pract. Lab. Med."},{"issue":"12","key":"10.1016\/j.cca.2025.120435_b0115","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1055\/s-0043-1770096","article-title":"Factors influencing Anti-Xa assays: a multicenter prospective study in critically Ill and noncritically Ill patients receiving unfractionated heparin","volume":"123","author":"Lasne","year":"2023","journal-title":"Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.cca.2025.120435_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102257","article-title":"Reassessment of dextran sulfate in anti-Xa assay for unfractionated heparin laboratory monitoring","volume":"7","author":"Hardy","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"10.1016\/j.cca.2025.120435_b0125","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/01.CIR.53.4.691","article-title":"Heparin kinetics in venous thrombosis and pulmonary embolism","volume":"53","author":"Hirsh","year":"1976","journal-title":"Circulation"},{"issue":"37","key":"10.1016\/j.cca.2025.120435_b0130","doi-asserted-by":"crossref","first-page":"35152","DOI":"10.1074\/jbc.M300925200","article-title":"Processing of macromolecular heparin by heparanase","volume":"278","author":"Gong","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"24","key":"10.1016\/j.cca.2025.120435_b0135","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1161\/01.CIR.103.24.2994","article-title":"Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association","volume":"103","author":"Hirsh","year":"2001","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.cca.2025.120435_b0140","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3390\/biomedicines9030264","article-title":"Updates on anticoagulation and laboratory tools for therapy monitoring of heparin, vitamin K antagonists and direct oral anticoagulants","volume":"9","author":"Kumano","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.cca.2025.120435_b0145","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40560-023-00701-3","article-title":"Variation in coagulation factor activity levels cause discrepancies between activated partial thromboplastin time and anti-Xa activity for heparin monitoring: a retrospective observational study","volume":"11","author":"Saito","year":"2023","journal-title":"J. Intensive Care"},{"issue":"8","key":"10.1016\/j.cca.2025.120435_b0150","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s12630-019-01391-y","article-title":"Pseudo heparin resistance caused by elevated factor VIII in a critically ill patient","volume":"66","author":"Downie","year":"2019","journal-title":"Can. J. Anaesth."},{"issue":"3","key":"10.1016\/j.cca.2025.120435_b0155","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/jth.13235","article-title":"Contact system revisited: an interface between inflammation, coagulation, and innate immunity","volume":"14","author":"Long","year":"2016","journal-title":"J. Thromb. Haemost."},{"issue":"17","key":"10.1016\/j.cca.2025.120435_b0160","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-569111","article-title":"Coagulation factor XII in thrombosis and inflammation","volume":"131","author":"Maas","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cca.2025.120435_b0165","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1751-553X.2010.01283.x","article-title":"Evaluation of activated partial thromboplastin time (aPTT) reagents for application in biomedical diagnostic device development","volume":"33","author":"Dudek","year":"2011","journal-title":"Int. J. Lab. Hematol."},{"issue":"2","key":"10.1016\/j.cca.2025.120435_b0170","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jacasi.2023.11.014","article-title":"Bleeding risk in asian patients: potential for thrombin amplification pathway blockade using factor XI inhibitors","volume":"4","author":"Liang","year":"2024","journal-title":"JACC Asia"},{"issue":"4","key":"10.1016\/j.cca.2025.120435_b0175","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jacc.2007.01.098","article-title":"Racial\/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation","volume":"50","author":"Shen","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.cca.2025.120435_b0180","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/qjmed\/90.8.535","article-title":"Heparin therapy in the Chinese\u2013lower doses are required","volume":"90","author":"Yu","year":"1997","journal-title":"QJM"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125003146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125003146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T20:07:10Z","timestamp":1762114030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898125003146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":36,"alternative-id":["S0009898125003146"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2025.120435","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative study and relevant exploration on methods for establishing unfractionated heparin therapeutic range (HTR) based on APTT","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2025.120435","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120435"}}